RenovoRx (RNXT) Capital Expenditures (2025 - 2026)
RenovoRx's (RNXT) quarterly Capital Expenditures came in at $200000.0 in Q2 2026, up 9900.0% quarter-over-quarter from $2000.0 in Q1 2025.
Powered by 
Analysis
RenovoRx (RNXT) Capital Expenditures (2025 - 2026) Analysis & Trends
RenovoRx has disclosed Capital Expenditures across 2 years of filings, most recently posting $200000.0 for Q2 2026.
- In Q2 2026, Capital Expenditures changed N/A year-over-year to $200000.0; the TTM figure through Jun 2026 stood at $200000.0 (changed N/A YoY), while the FY2025 annual figure was $2000.0, down 83.33% from the prior year.
- Capital Expenditures came in at $200000.0 for Q2 2026 at RenovoRx, up from $2000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $200000.0 in Q2 2026 to a low of $2000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 497.00 Mn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 112.60 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 503.00 Mn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 202.00 Mn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 195.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 66.90 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -96.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 84.70 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 87.50 Mn |
| 10 | RenovoRx | 83.48 Mn | 83.48 Mn | 766,000.00 | 200,000.00 |